Automatic Website Traffic RSS
Pulmonary Vascular Resistance | AutoTraffic FDA approves J&J’s OPSYNVI for pulmonary arterial hypertension
The US Food and Drug Administration (FDA) has granted approval for Johnson & Johnson's (J&J) OPSYNVI for chronic treatment of adult patients with pulmonary arterial hypertension (PAH), World Health ...
read more With Merck's key PAH approval on tap, Johnson & Johnson wins nod for combo tablet
The FDA has signed off on Opsynvi, a tablet which combines J&J’s Opsumit (macitanten) and United Therapeutics' Adcirca (tadalafil) which are commonly prescribed together to treat the condition.
read more FDA approves first-in-class drug for rare lung disorder
The US Food and Drug Administration has approved a fusion protein made by Merck & Co. for a rare, life-threatening lung disorder.
read more FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH
1 The secondary end points, tested hierarchically, were multicomponent improvement, change in pulmonary vascular resistance, change in N-terminal pro-B-type natriuretic peptide level, improvement in ...
read more FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension
The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.
read more FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
Winrevair is the first FDA-approved activin signaling inhibitor therapy for pulmonary arterial hypertension.
read more Johnson & Johnson Gets FDA Approval for Pulmonary Arterial Hypertension Pill
By Ben Glickman Johnson & Johnson's Opsynvi, a single-tablet combination of two existing compounds, has received approval from U.S. regulators to ...
read more Aerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data Release
TD Cowen analyst Joseph Thome has maintained their bullish stance on AVTE stock, giving a Buy rating today. Joseph Thome has given his Buy ...
read more Johnson & Johnson announces approval of OPSYNVI for pulmonary arterial hypertension patients
In a significant milestone for pulmonary arterial hypertension (PAH) patients, Johnson & Johnson has announced the approval of OPSYNVI.
read more J&J Wins FDA Nod for Pulmonary Arterial Hypertension Combo Pill
Johnson & Johnson’s Opsynvi has been approved by the FDA for the treatment of pulmonary arterial hypertension, combining macitentan, which cuts the risk of clinical worsening and hospitalization, ...
read more Merck gets USFDA nod for WINREVAIR (sotatercept-csrk) for adults with pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, ...
read more FDA Approves Single-Tablet Combination of Macitentan and Tadalafil for Pulmonary Arterial Hypertension
In clinical trials, the newly approved Opsynvi led to a greater drop in pulmonary vascular resistance after 16 weeks compared with both tadalafil and macitentan monotherapy.
read more Subscribe to RSS Feed